RO 5267683Alternative Names: RO5267683
Latest Information Update: 25 Feb 2014
At a glance
- Originator Roche
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 25 Feb 2014 Discontinued - Phase-I for Undefined indication in France (PO)
- 30 Jun 2012 Roche completes a phase I trial in Healthy volunteers in France (NCT01398241)
- 31 Aug 2011 Phase-I clinical trials in Undefined indication in France (PO)